Related Experiment Videos
PKC-beta is not necessary for cardiac hypertrophy
B B Roman1, D L Geenen, M Leitges
1Section of Cardiology, Department of Medicine, University of Illinois at Chicago, Illinois 60612, USA. broman@uic.edu
Summary
Ablating protein kinase C-beta (PKC-beta) did not prevent cardiac hypertrophy in mice. These findings indicate that the PKC-beta pathway is not essential for developing or attenuating cardiac hypertrophy.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Physiology
Background:
- Protein kinase C-beta (PKC-beta) activation is linked to pathological cardiac hypertrophy in human and rodent models.
- Targeting the PKC-beta pathway is a potential strategy to prevent or reverse cardiac hypertrophy.
Purpose of the Study:
- To investigate the necessity of PKC-beta in the development of cardiac hypertrophy.
- To determine if PKC-beta deficiency attenuates the hypertrophic response to stimuli.
Main Methods:
- Studied gene knockout (KO) mice lacking the PKC-beta gene.
- Assessed cardiac hypertrophy using phenylephrine (Phe) infusion and aortic banding (AoB) models.
- Measured heart weight-to-body weight ratio and atrial natriuretic factor mRNA levels.
Main Results:
- No significant differences in baseline hemodynamics or other PKC isoform expression between KO and control mice.
- PKC-beta KO mice exhibited cardiac hypertrophy in response to both Phe and AoB stimuli, similar to control animals.
- Ventricular atrial natriuretic factor mRNA was upregulated in KO animals, indicating a hypertrophic response.
Conclusions:
- PKC-beta expression is not required for the development of cardiac hypertrophy.
- The absence of PKC-beta does not attenuate the cardiac hypertrophic response to pharmacological or mechanical stress.